{"id":"cyclosporine-oral-product","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-25","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"20-40","effect":"Infection"},{"rate":"10-20","effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine binds to cyclophilin and the resulting complex inhibits calcineurin phosphatase, which prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of IL-2 and other cytokines essential for T-cell activation and proliferation, leading to immunosuppression. It is used to prevent organ rejection and treat autoimmune conditions.","oneSentence":"Cyclosporine suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing the production of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:38.597Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Autoimmune diseases including rheumatoid arthritis and nephrotic syndrome"},{"name":"Severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT00977977","phase":"PHASE2","title":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2010-12-22","conditions":"Nephrotic Syndrome, Proteinuria, Autoimmune Disease","enrollment":30},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT02203396","phase":"PHASE2","title":"A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2014-08","conditions":"Aplastic Anemia","enrollment":40},{"nctId":"NCT06892756","phase":"PHASE1","title":"Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00357565","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-11","conditions":"Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission","enrollment":34},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04017962","phase":"PHASE2","title":"A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-07-19","conditions":"CMV, CMV Infection, Hematopoietic Cell Transplant","enrollment":102},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT07043985","phase":"NA","title":"Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study","status":"COMPLETED","sponsor":"Badr University","startDate":"2018-01-03","conditions":"Tissue Modification After Vit c Injection","enrollment":20},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT05745701","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-22","conditions":"Healthy","enrollment":16},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT04788641","phase":"PHASE1","title":"Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-30","conditions":"Hyperkalaemia","enrollment":62},{"nctId":"NCT06004752","phase":"PHASE2","title":"Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-17","conditions":"Aplastic Anemia","enrollment":30},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT04532918","phase":"PHASE1","title":"Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-10","conditions":"Chronic Kidney Disease","enrollment":14},{"nctId":"NCT02745717","phase":"PHASE4","title":"The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT05573230","phase":"PHASE1","title":"A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-10-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT05459649","phase":"PHASE2","title":"Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-07-20","conditions":"Immune Thrombocytopenia","enrollment":253},{"nctId":"NCT05109390","phase":"PHASE1","title":"A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-27","conditions":"Healthy","enrollment":72},{"nctId":"NCT00051311","phase":"PHASE2","title":"Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-01-03","conditions":"Hematologic Neoplasms","enrollment":62},{"nctId":"NCT04023760","phase":"PHASE4","title":"Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2019-06-26","conditions":"Pharmacokinetics, Kidney Transplant, Lung Transplant","enrollment":14},{"nctId":"NCT01287078","phase":"PHASE2","title":"Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2011-01-29","conditions":"Constrictive Bronchiolitis, Bronchiolitis Obliterans, Graft vs Host Disease","enrollment":25},{"nctId":"NCT04149678","phase":"PHASE1","title":"Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-10-04","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT00568633","phase":"PHASE3","title":"Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-08","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT03466567","phase":"PHASE1","title":"A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-03-15","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":21},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT02280421","phase":"PHASE1","title":"Drug-Drug Interaction Study: ASP2151 and Ciclosporin","status":"COMPLETED","sponsor":"Maruho Europe Limited","startDate":"2014-10","conditions":"Healthy","enrollment":26},{"nctId":"NCT03768609","phase":"PHASE1","title":"A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2018-12-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT03801746","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2018-07-20","conditions":"Drug Interaction Potentiation","enrollment":40},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT00303667","phase":"PHASE1, PHASE2","title":"Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-01","conditions":"Acute Myelogenous Leukemia","enrollment":50},{"nctId":"NCT00354172","phase":"PHASE2","title":"Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-02","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT00686556","phase":"PHASE1","title":"Total Marrow Irradiation for Refractory Acute Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma","enrollment":12},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Leukemia, Mast-Cell, Mantle-cell Lymphoma","enrollment":36},{"nctId":"NCT02281370","phase":"PHASE1","title":"Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-05","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":39},{"nctId":"NCT03136237","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2017-02-17","conditions":"Hereditary Angioedema","enrollment":54},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT03083782","phase":"PHASE1","title":"Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2017-04-18","conditions":"Venous Thromboembolism, Pharmacokinetics, Healthy","enrollment":12},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT01313923","phase":"EARLY_PHASE1","title":"Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2011-02","conditions":"Pemphigus","enrollment":3},{"nctId":"NCT01514968","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-12","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT02630563","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Pediatric Liver Transplantation","enrollment":9},{"nctId":"NCT01762657","phase":"PHASE3","title":"The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Perle Bioscience, Inc.","startDate":"2014-09","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01762644","phase":"PHASE3","title":"The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients","status":"WITHDRAWN","sponsor":"Perle Bioscience, Inc.","startDate":"2015-08","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT02225756","phase":"PHASE2","title":"Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-12","conditions":"Abdominal Aortic Aneurysm,, Small Abdominal Aortic Aneurysm","enrollment":360},{"nctId":"NCT01109914","phase":"PHASE4","title":"Mucosal Response in Immunocompromised Host","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2010-04","conditions":"Kidney Transplantation, Immunity","enrollment":51},{"nctId":"NCT02392780","phase":"PHASE2","title":"Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease","status":"UNKNOWN","sponsor":"moshe yeshurun","startDate":"2015-04","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT00005937","phase":"PHASE2","title":"Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia","status":"COMPLETED","sponsor":"Neal Young, M.D.","startDate":"2000-06","conditions":"Myelodysplastic Syndrome","enrollment":42},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT01995331","phase":"PHASE4","title":"Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia","status":"UNKNOWN","sponsor":"Xiaofan Zhu","startDate":"2012-03","conditions":"Aplastic Anemia","enrollment":30},{"nctId":"NCT00658320","phase":"PHASE3","title":"Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Kidney Transplantation","enrollment":122},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT00005113","phase":"PHASE3","title":"A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"1999-07","conditions":"End-Stage Renal Disease, Kidney Transplantation","enrollment":102},{"nctId":"NCT01494597","phase":"PHASE1","title":"Drug Interaction Study of Isavuconazole and Cyclosporine","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT01446484","phase":"PHASE1, PHASE2","title":"Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection","status":"UNKNOWN","sponsor":"Pirogov Russian National Research Medical University","startDate":"2011-10","conditions":"End-Stage Renal Disease, Kidney Failure","enrollment":30},{"nctId":"NCT00187915","phase":"NA","title":"Pilot Trial for Implementation of a MPA PK Monitoring Strategy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-07","conditions":"Transplant, Kidney","enrollment":24},{"nctId":"NCT01276457","phase":"PHASE3","title":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-05","conditions":"Transplantation Infection","enrollment":223}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prednisone","Sandimmune","cyclosporine A"],"phase":"marketed","status":"active","brandName":"Cyclosporine Oral Product","genericName":"Cyclosporine Oral Product","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine suppresses T-cell activation and proliferation by inhibiting calcineurin, thereby reducing the production of pro-inflammatory cytokines. Used for Prevention of organ rejection in transplant recipients, Autoimmune diseases including rheumatoid arthritis and nephrotic syndrome, Severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}